C4 lays off 30% of staff in aftermath of BRD9 degrader discontinuation

Two months after C4 Therapeutics discontinued one of its cancer assets, the small molecule medicines biotech has revealed that this narrowing of focus will come at the cost of a 30% reduction in headcount.